<blockquote><span style="font-size:90%">Quote:<hr> <br> Dr. Edfjäll was responsible for the successful regulatory approval of 20 <b>innovative medicinal products</b> and new indications in more than 50 countries. The approved medicines include biotech, low-molecular and plasma derived products, <b>notably also for several oncology</b> and haematology indications as well as many rare diseases. In her most recent leadership role, she was the global head of regulatory affairs at the Australian company CSL Behring. Prior to that, she held leadership positions in regulatory affairs at both start-up and mid-size biotech and pharma companies (formerly known as Actelion, Celgene and Shire), she started her career in regulatory affairs at F. Hoffmann-La Roche</span><hr></blockquote> <a href="https://cddf.org/about-cddf/organisation/board-members/dr-catarina-edfjall/" rel="nofollow noopener noreferrer ugc" target="_blank">https://cddf.org/about-cddf/organisation/board-members/dr-catarina-edfjall/</a> <br> <br> The Cancer Drug Development Forum (CDDF) is an international, non-profit organisation registered in Belgium that provides a neutral platform to stimulate interaction between stakeholders involved in cancer drug development. <br> <br> The CDDF’s mission is to facilitate collaboration between stakeholders, to increase efficiency in cancer drug development and accelerate the delivery of effective oncology treatment to patients. <br> <br> Its integrative approach brings together leading voices from academia, the pharmaceutical industry, regulatory authorities, policymakers and patient advocacy groups to improve cancer treatment.